⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CLRB News
Cellectar Biosciences INC NEW
Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million
globenewswire.com
CLRB
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
globenewswire.com
CLRB
Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer
globenewswire.com
CLRB